Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Avidity Biosciences, Inc. RNA
$10.92
-$0.26 (-2.41%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
820016856.00000000
-
week52high
25.74
-
week52low
9.83
-
Revenue
9224000
-
P/E TTM
-4
-
Beta
-0.09946900
-
EPS
-2.83000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Buy | 20 июл 2022 г. | |
| Raymond James | Strong Buy | 12 июл 2022 г. | |
| SVB Leerink | Outperform | Outperform | 11 мая 2022 г. |
| Credit Suisse | Outperform | Outperform | 11 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 10 дек 2021 г. |
| Needham | Buy | Buy | 27 сент 2022 г. |
| Chardan Capital | Buy | Buy | 27 сент 2022 г. |
| Raymond James | Strong Buy | Strong Buy | 09 ноя 2022 г. |
| Credit Suisse | Outperform | Outperform | 09 ноя 2022 г. |
| Wells Fargo | Overweight | Overweight | 04 янв 2023 г. |
| Raymond James | Strong Buy | Strong Buy | 15 дек 2022 г. |
| Credit Suisse | Outperform | Outperform | 15 дек 2022 г. |
| Raymond James | Strong Buy | Strong Buy | 14 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Boyce Sarah | D | 1097015 | 3221 | 03 февр 2023 г. |
| Boyce Sarah | D | 53352 | 3221 | 03 февр 2023 г. |
| Boyce Sarah | A | 56573 | 3221 | 03 февр 2023 г. |
| Boyce Sarah | D | 1100236 | 45879 | 02 февр 2023 г. |
| Boyce Sarah | D | 53352 | 45879 | 02 февр 2023 г. |
| Boyce Sarah | A | 99231 | 45879 | 02 февр 2023 г. |
| Boyce Sarah | D | 1146115 | 900 | 01 февр 2023 г. |
| Boyce Sarah | D | 53352 | 900 | 01 февр 2023 г. |
| Boyce Sarah | A | 54252 | 900 | 01 февр 2023 г. |
| Flanagan W. Michael | A | 144000 | 144000 | 20 янв 2023 г. |
Новостная лента
5 Best and Worst Performing Small-Cap Stocks in Dec 2022
24/7 Wall Street
17 янв 2023 г. в 22:59
Small-cap stocks usually suffer more than mid- and large-cap stocks when the market as a whole is struggling, and when the market is rallying, they could offer higher returns as well.
Avidity Biosciences Will Rise As It Revolutionizes The Field Of RNA Therapeutics
Seeking Alpha
23 дек 2022 г. в 07:12
Avidity Biosciences possesses the only RNA agent capable of being delivered into the muscle. The company's platform success opens up its pipeline to rare muscle diseases and previously unreachable tissue targets such as cardiac muscle.
Avidity Biosciences: Unique Antibody-Oligonucleotide Conjugate Technology
Seeking Alpha
22 дек 2022 г. в 05:22
Avidity Biosciences' stock was up 55% last week after releasing preliminary data from a Phase 1/ 2 study of its antibody-oligonucleotide technology candidate in treating myotonic dystrophy type 1. The next price-moving catalyst is the updated Phase 1/2 MARINA trial data in 2023 (likely in mid-2023).
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners
The Motley Fool
14 дек 2022 г. в 13:44
Business wins are shining the spotlight on these two companies.
RNA Breakthrough Sends Biotech Stock Surging
Schaeffers Research
14 дек 2022 г. в 10:04
Avidity Biosciences Inc (NASDAQ:RNA) is soaring this morning, after the biotech company shared positive data from a trial demonstrating the first-ever successful targeted delivery of RNA into muscle.